enGene Therapeutics Inc. (ENGNW)
enGene Therapeutics Inc. (ENGNW)
| Cash Flow | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
| Net loss | -30,227 | -29,752 | -37,880 | -79,422 |
| Non-cash interest expense | 136 | 183 | 209 | 645 |
| Loss on extinguishment of debt | 0 | -488 | NaN | NaN |
| Loss on impairment of assets | 147 | NaN | NaN | NaN |
| Non-cash lease expense | -243 | -246 | -253 | -125 |
| Net amortization of premiums (accretion of discounts) on marketable securities | NaN | NaN | -3,067 | NaN |
| Accretion of marketable securities | 494 | -2,054 | NaN | 2,645 |
| Unrealized foreign currency losses | 29 | -69 | 25 | -28 |
| Share-based compensation expense | 4,145 | 2,803 | 2,606 | 7,040 |
| Depreciation of property and equipment | 180 | 189 | 171 | 338 |
| Investment tax credit receivable | -375 | 271 | 217 | 378 |
| Prepaid expenses and other assets | 1,582 | 2,422 | -1,986 | -3 |
| Accounts payable | -625 | -4,270 | 3,972 | 970 |
| Accrued expenses and other current liabilities | -2,485 | 4,386 | 4,154 | -1,024 |
| Lease liabilities | -282 | 39 | 231 | 43 |
| Net cash used in operating activities | -30,498 | -28,903 | -24,962 | -74,277 |
| Purchases of property and equipment | 98 | 153 | 437 | 1,048 |
| Purchases of marketable securities | 50,214 | 169,187 | 7,748 | 153,095 |
| Proceeds from maturities of marketable securities | 73,950 | 43,043 | 48,685 | 88,505 |
| Net cash used in investing activities | 23,638 | -126,297 | 40,500 | -65,638 |
| Proceeds from second amended term loan | 0 | 25,000 | NaN | NaN |
| Repayment of amended term loan principal | 0 | 23,053 | 0 | 699 |
| Payment of issuance costs associated with second amended term loan | -70 | 615 | NaN | NaN |
| Proceeds from issuance of pre-funded warrants | 1 | 23,249 | NaN | NaN |
| Proceeds from public offering | 0 | 126,250 | NaN | NaN |
| Payment of issuance cost associated with public offering and pre-funded warrants | 0 | 9,448 | NaN | NaN |
| Proceeds from exercise of stock options | 3 | 277 | 1,991 | 232 |
| Net cash provided by financing activities | 74 | 141,660 | 1,991 | -467 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 1 | 0 | 1 |
| Net decrease in cash and cash equivalents | -6,786 | -13,539 | 17,529 | -140,381 |
| Cash and cash equivalents at beginning of period | 36,613 | 50,152 | 173,004 | NaN |
| Cash and cash equivalents at end of period | 29,827 | 36,613 | 50,152 | NaN |